329P ORCHARD: Osimertinib + necitumumab in patients (pts) with advanced NSCLC whose disease progressed on first-line (1L) osimertinibJonathan W. Riess, H.A. Yu, Z. Piotrowska et al.|Annals of Oncology|2022Cited by 4